C07D 281/16
[b, f]-condensed
C07D281/16 ([b, f]-condensed) appears on 94 US grants and 96 published applications in this corpus.
Search patents in C07D- Granted patents
- 94
- Published applications
- 96
- Assignees
- 68
- Inventors
- 283
- Latest grant
- 25 Aug 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1981 | 1 | 0 |
| 1982 | 1 | 0 |
| 1983 | 0 | 0 |
| 1984 | 0 | 0 |
| 1985 | 0 | 0 |
| 1986 | 0 | 0 |
| 1987 | 0 | 0 |
| 1988 | 1 | 0 |
| 1989 | 1 | 0 |
| 1990 | 0 | 0 |
| 1991 | 0 | 0 |
| 1992 | 0 | 0 |
| 1993 | 3 | 0 |
| 1994 | 5 | 0 |
| 1995 | 7 | 0 |
| 1996 | 4 | 0 |
| 1997 | 5 | 0 |
| 1998 | 7 | 0 |
| 1999 | 2 | 0 |
| 2000 | 1 | 0 |
| 2001 | 0 | 1 |
| 2002 | 2 | 2 |
| 2003 | 1 | 2 |
| 2004 | 0 | 3 |
| 2005 | 1 | 2 |
| 2006 | 2 | 7 |
| 2007 | 3 | 9 |
| 2008 | 3 | 6 |
| 2009 | 2 | 8 |
| 2010 | 5 | 8 |
| 2011 | 6 | 7 |
| 2012 | 2 | 2 |
| 2013 | 4 | 0 |
| 2014 | 1 | 5 |
| 2015 | 1 | 2 |
| 2016 | 4 | 6 |
| 2017 | 3 | 3 |
| 2018 | 1 | 6 |
| 2019 | 4 | 3 |
| 2020 | 3 | 1 |
| 2021 | 3 | 4 |
| 2022 | 0 | 0 |
| 2023 | 2 | 5 |
| 2024 | 1 | 1 |
| 2025 | 1 | 1 |
| 2026 | 1 | 2 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Salts of neuroceuticals and uses thereof25 Aug 2026US 12,714,711 B2SyneuRx International (Taiwan) Corp.
- c-Abl tyrosine kinase inhibitory compound embodiments and methods of making and using the same7 Oct 2025US 12,435,047 B2Pontifica Universidad Catoclica de Chile
- Plasmodial surface anion channel inhibitors for the treatment or prevention of malaria13 Aug 2024US 12,059,418 B2The United States of America, as represented by the Secretary, Department of Health and Human Services
- Hepatitis b core protein modulators14 Nov 2023US 11,814,376 B2Assembly Biosciences, Inc.
- C-Abl tyrosine kinase inhibitory compound embodiments and methods of making and using the same16 May 2023US 11,649,218 B2Pontificia Universidad Catolica De Chile
- Slack-activating compounds and their medical use3 Sep 2026US 2026/0258003 A1
- Small molecule inhibitors of the ribosome biogenesis factor NVL29 Apr 2026US 2026/0097047 A1Board of Regents, The University of Texas System
- C-abl tyrosine kinase inhibitory compound embodiments and methods of making and using the same6 Nov 2025US 2025/0340521 A1Pontificia Universidad Catolica De Chile
- Hepatitis b core protein modulators25 Jan 2024US 2024/0025890 A1Assembly Biosciences, Inc.
- Inhibitors of the plasmodial surface anion channel as antimalarials2 Nov 2023US 2023/0346797 A1The United States of America, as represented by the Secretary, Department of Health and Human Services
Most cited
By later US patents
- Novel dibenzothiazepine antipsychotic65US 4,879,288 AICI Americas Inc. · 1989
- Tricyclic benzazepine vasopressin antagonists50US 5,512,563 AAmerican Cyanamid Company · 1996
- Antiviral dibenzothiazepinone derivatives44US 5,607,929 AGlaxo Wellcome Inc. · 1997
- 2-, 3-, 4-, 5-, 6-, 7-, 8-, 9- and/or 10-substituted dibenzoxazepine and dibenzthiazepine compounds, pharmaceutical compositions and methods of use43US 5,354,747 AG. D. Searle & Co. · 1994
- Treatment of CNS disorders using CNS target modulators35US 7,355,042 B2Hypnion, Inc. · 2008